Form 4: Dyne Therapeutics Chief Scientific Officer Oxana Beskrovnaya Sells Shares to Cover Tax Obligations

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold 2,373 shares of common stock on March 7, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Summary

• On March 7, 2024, Oxana Beskrovnaya, the Chief Scientific Officer of Dyne Therapeutics, sold 2,373 shares of the company's common stock.
• The sale was executed at a weighted average price of $25.85 per share, with individual transactions ranging from $25.84 to $26.33.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) granted on November 15, 2023.
• The sale was automated under a pre-existing agreement, aligning with Rule 10b5-1(c) to avoid discretionary trading concerns.
• Following the transaction, Beskrovnaya still beneficially owns 154,433 shares, including 140,948 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations, which is a common practice and doesn't necessarily reflect a change in the executive's confidence in the company.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and do not necessarily indicate a negative outlook on the company's future.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units, which vest over time.
• Upon vesting, these equity awards are subject to income tax, and executives often sell a portion of their shares to cover these tax liabilities.
• This practice is common across the biotechnology industry, with companies like Sarepta Therapeutics and BioMarin Pharmaceutical seeing similar transactions by their executives.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, but the explanation provided mitigates this concern.
• The transaction is unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates